0001193125-18-027466.txt : 20180306 0001193125-18-027466.hdr.sgml : 20180306 20180131162103 ACCESSION NUMBER: 0001193125-18-027466 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESSA Pharma Inc. CENTRAL INDEX KEY: 0001633932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (778) 331-0962 MAIL ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 CORRESP 1 filename1.htm CORRESP

January 31, 2018

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: ESSA Pharma Inc.

Registration Statement on Form F-3

File No. 333-222654

Ladies and Gentlemen:

ESSA Pharma Inc., a corporation incorporated under the Business Corporations Act (British Columbia), hereby requests, pursuant to Rule 461(a) under the Securities Act of 1933, as amended, that the effective date of the Company’s registration statement (the “Registration Statement”) on Form F-3 (File No. 333-222654) be accelerated by the Securities and Exchange Commission (the “Commission”) to 4:00 pm, Eastern Time, on Friday February 2, 2018, or as soon thereafter as practicable.

We request that we be notified of such effectiveness by a telephone call to Colin Brown of Skadden, Arps, Slate, Meagher & Flom LLP, the Company’s counsel, at (416) 777-4700 and that such effectiveness also be confirmed in writing.

 

Very truly yours,
ESSA PHARMA INC.
By:   /s/ David Wood
  Name: David Wood
  Title:   Chief Financial Officer